SAFC To Provide Chemical Services to Affichem

SAFC Pharma, a member of the Sigma-Aldrich Group, has been appointed by Affichem to provide chemical development services relating to Dendrogenine A, a new first-in-class molecule currently in preclinical development for the potential treatment of aggressive cancers. This compound contains an original mechanism of action, which makes tumor-producing, tumor-specific antigens and activates the cytotoxic T response against the tumor through the stimulation of the monocyte differentiation into “dendritic-like” cells.

SAFC will conduct process R&D on the synthesis of the material to determine a suitable process for producing sufficient quantities of Dendrogenine A for future clinical trials and cGMP commercial production. Stephane Silvente, Affichem’s chief executive officer, remarked, “We are very pleased to be able to draw upon SAFC’s chemical development expertise to assist us with this part of the Dendrogenine A development program.”

SAFC president Frank Wicks said, “Our chemical development partnership with Affichem to work on this program is one example of how SAFC’s capabilities support the chemistry requirements of emerging and established pharmaceutical companies. SAFC’s strategy combines experienced scientific talent with state-of-the-art technologies and facilities to offer customers a faster and more efficient method to obtain the high quality drug candidates they seek.”